seroprevalence of human t-cell leukemia virus type-1 (htlv-1) in high risk patients
Authors
abstract
background: human t-lymphotropic virus type i is the etiologic agent of two distinct human diseases, adult t-cell leukemia or lymphoma and a chronic, progressive demyelinating disorder. the aim of this work was to investigate the seroprevalence of htlv-1/2 among high risk patients (thalassemic and hemodialysis) in charmahal-va-baktiari province, center of iran. methods: using elisa, a total of 357 serum samples from the patients were tested for htlv specific antibody during first 6 month of 2005. seventy percent of samples were thalassemics and 30% were hemodialysis patients. all of the elisa positive samples were confirmed by western blotting (wb) analysis. results: using elisa, 27 of 357 (7.6%) serum samples tested positive for htlv-1 specific antibody of which 18 (7.2%) were thalassemic and 9 (8.4%) were hemodialysis patients. the wb results showed that of 27 samples tested positive by elisa, 24 (89%) were htlv-1 and 3 (11%) were not confirmed. conclusion: the relatively high seroprevalence of htlv-1 among both thalassemic and hemodialysis patients was determined in this province. this might indicate this region as an endemic area for this virus. however, to approve this hypothesis, the prevalence of this virus in the blood donors has to be determined.
similar resources
The Enigma of Human T-Cell Leukemia Virus Type-1 (HTLV-1) Infection in Iran
Human T-cell lymphotropic virus type-I (HTLV-I) was the first human retrovirus associated with malignancy. The prevalence of HTLV-I infection varies significantly in different regions of the world. In this study, the prevalence of HTLV-I infection among ethnic Jews living in Shiraz, South of Iran, was investigated. 286 blood samples were obtained. HTLV-1 antibody assay on serum samples was d...
full textthe enigma of human t-cell leukemia virus type-1 (htlv-1) infection in iran
human t-cell lymphotropic virus type-i (htlv-i) was the first human retrovirus associated with malignancy. the prevalence of htlv-i infection varies significantly in different regions of the world. in this study, the prevalence of htlv-i infection among ethnic jews living in shiraz, south of iran, was investigated. 286 blood samples were obtained. htlv-1 antibody assay on serum samples was d...
full textFrequency of Human T-Cell Lymphotropic Virus (HTLV) Type 1 and 2 Infection in HIV Infected Patients
Background and Objectives: Human T-cell lymphotropic viruses (HTLV) type 1 and 2 are retroviruses that share the same routes of transmission as human immunodeficiency virus (HIV). As a consequence of epidemiologic similarities, HIV and HTLV-1/2 co-infection is frequent. Due to the limited data, this study assessed the seroprevalence of HTLV-1/2 infections in HIV infected patients in Tehran, Ira...
full textIncidence of Human T-Lymphotropic Virus Type 1 (HTLV-1) among Blood Donors from Ilam, Iran
full text
Awareness of laboratory students of Mashhad University of Medical Sciences about human T-cell lymphotropic virus type 1 (HTLV-1)
Introduction: HTLV-1 virus is a human retrovirus and it causes several chronic diseases. So far, there is not any vaccine or satisfactory treatment that has been developed for infections caused by this virus. Moreover, the best way to control the infection is prevention and the best way to prevent it is education. Therefore, our study was conducted to investigate the knowledge and attitudes of ...
full textHigh proviral load of human T cell lymphotropic virus type-1 facilitates coronary artery diseases
Objective(s): Coronary artery disease (CAD) is known as a life threatening disease, worldwide. In this study the role of HTLV-1 infection was evaluated on cardiac involvement in an endemic region of northeastern Iran.Materials and Methods: Serologic and molecular tests for HTLV-1 infection were carried out in subjects who had coronary an...
full textMy Resources
Save resource for easier access later
Journal title:
journal of research in health sciencesجلد ۶، شماره ۲، صفحات ۴۴-۰
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023